Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 4;79(1):66-82.
doi: 10.1016/j.jacc.2021.10.035.

Coronary Atherosclerotic Plaque Regression: JACC State-of-the-Art Review

Affiliations
Free article
Review

Coronary Atherosclerotic Plaque Regression: JACC State-of-the-Art Review

Luke P Dawson et al. J Am Coll Cardiol. .
Free article

Abstract

Over the last 3 decades there have been substantial improvements in treatments aimed at reducing cardiovascular (CV) events. As these treatments have been developed, there have been parallel improvements in coronary imaging modalities that can assess plaque volumes and composition, using both invasive and noninvasive techniques. Plaque progression can be seen to precede CV events, and therefore, many studies have longitudinally assessed changes in plaque characteristics in response to various treatments, aiming to demonstrate plaque regression and improvements in high-risk features, with the rationale being that this will reduce CV events. In the past, decisions surrounding treatments for atherosclerosis have been informed by population-based risk scores for initiation in primary prevention and low-density lipoprotein cholesterol levels for titration in secondary prevention. If outcome data linking plaque regression to reduced CV events emerge, it may become possible to directly image plaque treatment response to guide management decisions.

Keywords: atherosclerotic plaque; coronary artery disease; imaging; ischemic heart disease; plaque modification.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures Dr Nicholls has received research support from AstraZeneca, Amgen, Anthera, CSL Behring, Cerenis, Eli Lilly, Esperion, Reverlogix, Novartis, InfraRedx, New Amsterdam Pharmaceuticals, and Sanofi-Regeneron; and is a consultant for Amgen, Akcea, AstraZeneca, Amarin, Boehringer Ingelheim, CSL Behring, Eli Lilly, Esperion, Kowa, Merck, Takeda, Pfizer, Sanofi-Regeneron, and Novo Nordisk. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

MeSH terms